%PDF-1.4
%
132 0 obj
<>
endobj
129 0 obj
<>
endobj
199 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-06-03T14:51:09Z
2024-03-28T04:01:42-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T04:01:42-07:00
application/pdf
Heather
2004-797.july
uuid:ebc87644-1dd1-11b2-0a00-4808278d5b00
uuid:ebc87648-1dd1-11b2-0a00-1e0000000000
endstream
endobj
116 0 obj
<>
endobj
118 0 obj
<>
endobj
117 0 obj
<>
endobj
119 0 obj
<>
endobj
84 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 110 0 R/Type/Page>>
endobj
200 0 obj
[205 0 R]
endobj
201 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
8 0 0 8 53.8216 56.7343 Tm
(1242)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:7)Tj
ET
0 0 0 0 k
/GS0 gs
104.631 81.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
104.631 81.583 407.5 -10.833 re
S
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tw 10 0 0 10 53.468 735.6616 Tm
(REFERENCES)Tj
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 60.668 725.6616 Tm
[(1.)-600.1 (Arend )17.7 (WPD, Dayer JM. Cytokines and cytokine inhibitors or )]TJ
1.35 -1.25 Td
[(antagonists in rheumatoid arthritis. )54.8 (Arthritis Rheum 1990;33:305-15.)]TJ
-1.35 -1.25 Td
[(2.)-600.1 (Bathon JM, Martin R)54.8 (W)91.8 (, Fleischmann RM, et al. )54.8 (A)-220.1 (comparison of)]TJ
1.35 -1.25 Td
(etanercept and methotrexate in patients with early rheumatoid )Tj
0 -1.25 TD
(arthritis. N Engl J Med 2000;343:1586-93.)Tj
-1.35 -1.25 Td
[(3.)-600.1 (Klareskog L, van der Heijde DM, de Jager JP)110.7 (, et al. )17.7 (Therapeutic)]TJ
1.35 -1.25 Td
[(ef)17.7 (fect of the combination of etanercept and methotrexate compared)]TJ
T*
(with each treatment alone in patients with rheumatoid arthritis: )Tj
T*
(double-blind randomised controlled trial. Lancet 2004;363:675-81.)Tj
-1.35 -1.25 Td
[(4.)-600.1 (Lipsky PE, van der Heijde DM, St. Clair EW)91.7 (, et al. Infliximab and)]TJ
1.35 -1.25 Td
(methotrexate in the treatment of rheumatoid arthritis. N Engl J Med)Tj
0 Tc 0 Tw T*
(2000;343:1594-602.)Tj
-0.00011 Tc 0.02499 Tw -1.35 -1.25 Td
[(5.)-600.1 (Keystone E, Kavanaugh )54.8 (AF)79.7 (, Sharp J, et al. )54.8 (Adalimumab \(D2E7\), a)]TJ
1.35 -1.25 Td
(fully human anti-TNF-)Tj
/T1_3 1 Tf
0 Tc 0 Tw [-0.1 (\003)]TJ
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 10.1197 0 Td
[(monoclonal antibody)64.8 (, inhibits the )]TJ
-10.1197 -1.25 Td
(progression of structural joint damage in patients with active RA)Tj
T*
[(despite concomitant methotrexate therapy [abstract]. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2002;46 Suppl:S205.)Tj
-0.00011 Tc -1.35 -1.25 Td
[(6.)-600.1 (Genovese MC, Bathon JM, Martin R)54.8 (W)91.8 (, et al. Etanercept versus)]TJ
1.35 -1.25 Td
(methotrexate in patients with early rheumatoid arthritis: two-year)Tj
T*
[(radiographic and clinical outcomes. )54.8 (Arthritis Rheum )]TJ
0 Tc 0 Tw T*
(2002;46:1443-50.)Tj
-0.00011 Tc 0.02499 Tw -1.35 -1.25 Td
[(7.)-600.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Boers M, et al. )17.7 (The )54.8 (American College of)]TJ
1.35 -1.25 Td
(Rheumatology preliminary core set of disease activity measures for)Tj
T*
[(rheumatoid arthritis clinical trials. )17.7 (The Committee on Outcome)]TJ
T*
[(Measures in Rheumatoid )54.8 (Arthritis Clinical )17.7 (T)35 (rials. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1993;36:729-40.)Tj
-0.00011 Tc 0.02499 Tw -1.35 -1.25 Td
[(8.)-600.1 (van der Heijde DM, van \325)17.7 (t Hof MA, van Riel PL, et al. Judging )]TJ
1.35 -1.25 Td
(disease activity in clinical practice in rheumatoid arthritis: first ste\
p)Tj
T*
[(in the development of a disease activity score 1. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(1990;49:916-20.)Tj
-0.00011 Tc 0.02499 Tw -1.35 -1.25 Td
[(9.)-600.1 (van Riel PLCM. DAS-Score NL. )54.8 (A)74 (vailable from: )]TJ
-0.0298 Tw 1.35 -1.25 Td
[(http://www)64.8 (.reuma-nijmegen.nl/www)64.9 (.das-score.nl. Accessed )-54.8 (March)]TJ
0 Tc 0.02499 Tw T*
(29, 2005.)Tj
-0.00011 Tc -1.85 -1.25 Td
[(10.)-600.1 (Sharp JT)73.9 (, Lidsky MD, Collins LC, Moreland J. Methods of scoring)]TJ
1.85 -1.25 Td
(the progression of radiologic changes in rheumatoid arthritis.)Tj
T*
(Correlation of radiologic, clinical and laboratory abnormalities.)Tj
T*
(Arthritis Rheum 1971;14:706-20.)Tj
-1.8131 -1.25 Td
[(1)36.8 (1)-0.1 (.)-600.1 (van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual)]TJ
1.8131 -1.25 Td
(radiographic assessments of hands and feet in a three-year )Tj
T*
(prospective follow up of patients with early rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1992;35:26-34.)Tj
31.15 51.421 Td
[(12.)-600.1 (National Cancer Institute. Surveillance, Epidemiology)64.8 (, and End)]TJ
1.85 -1.25 Td
(Results \(SEER\) Program Public-Use Data \(1973-1999\), DCCPS,)Tj
T*
(Surveillance Research Program, Cancer Statistics Branch, released)Tj
T*
(April 2002, based on the November 2001 submission. Bethesda,)Tj
T*
(MD: National Cancer Institute; 2002.)Tj
-1.85 -1.25 Td
[(13.)-600.1 (Harris RB, Grif)17.7 (fith K, Moon )17.7 (TE. )17.7 (T)35 (rends in the incidence of )]TJ
1.85 -1.25 Td
[(nonmelanoma skin cancers in southeastern )54.8 (Arizona, 1985-1996. )]TJ
-0.0298 Tw T*
[(J Am Acad )-54.8 (Dermatol )-54.8 (2001;45:528-36.)]TJ
0.02499 Tw -1.85 -1.25 Td
[(14.)-600.1 (W)79.9 (olfe F)79.7 (, Michaud K. L)54.8 (ymphoma in rheumatoid arthritis. )17.7 (The ef)17.7 (fect)]TJ
1.85 -1.25 Td
(of methotrexate and anti-tumor necrosis factor therapy in 18,572)Tj
T*
[(patients. )54.8 (Arthritis Rheum 2004;50:1740-51.)]TJ
-1.85 -1.25 Td
[(15.)-600.1 (Kochanek KD, Smith BL, )54.8 (Anderson RN. Deaths: preliminary data)]TJ
1.85 -1.25 Td
[(for 1999. National )17.7 (V)59.8 (ital Statistics Reports 2001;49:1-48.)]TJ
-1.85 -1.25 Td
[(16.)-600.1 (Singh G, Ramey DR, Rausch PL, Schettler JD. Serious infections in)]TJ
1.85 -1.25 Td
(rheumatoid arthritis: relationship to immunosuppressive use)Tj
T*
[([abstract]. )54.8 (Arthritis Rheum 1999;42 Suppl:S242.)]TJ
-1.85 -1.25 Td
[(17.)-600.1 (Doran MF)79.7 (, Crowson CS, Pond GR, O\325Fallon )17.7 (WM, Gabriel SE.)]TJ
1.85 -1.25 Td
(Frequency of infection in patients with rheumatoid arthritis )Tj
T*
[(compared with controls: a population-based study)64.8 (. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2002;46:2287-93.)Tj
-0.00011 Tc 0.02499 Tw -1.85 -1.25 Td
[(18.)-600.1 (Food and Drug )54.8 (Administration. )54.8 (Arthritis advisory committee )]TJ
1.85 -1.25 Td
(meeting briefing document for Enbrel)Tj
0 Tc 0 Tw 6 0 0 6 457.5513 529.6693 Tm
(\250)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 464.3099 527.0293 Tm
[(\(etanercept\). 2003. )54.8 (A)74 (vailable)]TJ
-0.0002 Tc 0 Tw -16.1052 -1.25 Td
(from:)Tj
-0.00011 Tc T*
[(http://www)64.8 (.fda.gov/ohrms/dockets/ac/03/briefing/3930B1_03_A-)]TJ
0.02499 Tw T*
[(Amgen-Enbrel.pdf. )54.8 (Accessed March 29, 2005.)]TJ
-1.85 -1.25 Td
[(19.)-600.1 (Hulsmans HMJ, Jacobs JWG, van der Heijde DM, )54.8 (Albada-Kuipers)]TJ
1.85 -1.25 Td
[(GA, Schenk )36.8 (Y)128.9 (, Bijlsma JWJ. )17.7 (The course of radiologic damage )]TJ
T*
[(during the first six years of rheumatoid arthritis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2000;43:1927-40.)Tj
-0.00011 Tc 0.02499 Tw -1.85 -1.25 Td
[(20.)-600.1 (V)110.8 (an )54.8 (Aken J, Lard L, le Cessie S, Hazes J, Breedveld F)79.7 (, Huizinga )17.7 (T)74 (.)]TJ
1.85 -1.25 Td
(Radiological outcome after four years of early versus delayed )Tj
T*
(treatment strategy in patients with recent onset rheumatoid arthritis.)Tj
0 Tc T*
(Ann Rheum Dis 2004;63:274-9.)Tj
-0.00011 Tc -1.85 -1.25 Td
[(21.)-600.1 (Landewe RBM, Boers M, )17.7 (V)110.8 (erhoeven )54.8 (AC, et al. COBRA)]TJ
1.85 -1.25 Td
(combination therapy in patients with early rheumatoid arthritis.)Tj
T*
[(Long-term structural benefits of a brief intervention. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2002;46:347-56.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_4 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
110 0 obj
<>stream
8;Z\7dC+Z]#ikr7OPdT]>*>P\
$WCRmUQFX!L6$rI\-a>,+%-I!:Ll$!%1BTfaAa2IZV(
CTu]/'FecaHg@DM@*K;"-QBEFSLD:+'C]AM$!k)H>Q6#(PcBP1`s?oedr`p9Cg
iIH(.+%PR7FJ@@U#T0>gAQBokoP,e":r9AI0QBp(E$^1BWBEdRkto#4g+Q"DH%0hV
3K9!9f*<>TA)c]+^XI3U!%acJRYf2H>4=`HM6q8%Fm_WsO)4draukr&M6cqb,'f\,
!>Kr^0armH,NnY
/QRY:56l'QWC%:R(hMOF8WoEn-S-rB.s/;0hr[+\k7AHbJPfD#/O9G"=c&W)Z:eTW
*oK0*qDp'i=.[+g[(68INhsBbUbdA?$Mj3gO#B(u`VSU!6^C<$/9Lo\bhb$VINn]bmH?;;GI0u\/rB@)ZE3dr[f[*[b9O<
I
endstream
endobj
114 0 obj
[/Indexed/DeviceRGB 255 113 0 R]
endobj
113 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
140 0 obj
<>
endobj
87 0 obj
<>
endobj
144 0 obj
<>
endobj
160 0 obj
<>
endobj
176 0 obj
<>
endobj
204 0 obj
<>
endobj
158 0 obj
<>
endobj
156 0 obj
<>
endobj
157 0 obj
<>stream
HTPn -/JTE.\8IoB:¸߇I)u6^w`D\5uPI0V#*> ݶ$[7zh?srIqS̓=`nWn
3#㗷>\sh-|u,kQt{0QZ@H2!O sMę^*"c:U<)}d.W1f'BɶG>JzW +s.
endstream
endobj
159 0 obj
<>stream
Hbd`ab`ddspssMFyr<ww<9#]KLZ1'841'(5$N)Hx3#c'c;#~Wn~'*ȍOSa-s˰iY]R;/Vs8_+H}Yq5kl+}Dn]VV;ޛ{NO}gIXr|J:FKVŤ\-|Xut*wJo[=wB.0=T:`BEK/9}s?$~ZEo_~g^ߒ@47ސESYy|*Ufo|H$;߯"2,E 6
endstream
endobj
145 0 obj
<>
endobj
168 0 obj
<>stream
H|T PW{aiG7#*x `++C.1ȡ", 2D6
Q,Qcbnvq{&m4TY[GI,0iP5Α)U2A N0BQ"vOv$b4Rh3x{9Fe}^WWEhҲ2bQyX`2.=&7NVFdgSҕAmFP-R*}puZO_LLWZU:Eݮ+CS5YijoR*E\ΘĸD6Q+U[6Faf#f*ՎÚ1,\T`RSĽxޏ`!.Id%+%~GJN-"KiTBSRXɬnNuZO+M/~mg8pq^5j6>kooeeӡ7l ۤX8))gM&XelC DS/à=10;y&gA ? Ym`3
xj_i۶q݃W^
g⨔1uYu%ΐSE棙oϽpp'/7.
kWZke%hgq {`ap߯/fYyr2Pb&>_
~5V`+aXm6U\iEyi(_oc)L+2V0G>,\ZÝ<Z4,T=7tg.O%xS_
v2 nD9,r
D[k7b+lauP̈́R16Ko<}vL䟉%z2)?y4x3}F@cUxdlK eP|P&B6(B 2TBx(HS>xtO
t%sǮ5o / +dac A3]dH~o%h%KnB)\cyXNvs_#F
T)Q,̭EzI5Z'kEa(Ь ;
N7t
{6.NF\}1R{oL1Թv&TX025=Pp``a[)9)}yHi=xNHQ
Pd(z(m~d?$0/?o)d
o3rg7=.*`E1uGa1X'yї;{YrZE(8wCnaP
(~bX',]nR$ A-(u3/~[օWuSu5t@BVƇ/!D3f2l~rPhy 41ZW@s+r`' Me6BVnSrE+AΉVG}?ȥsI|+$}aw꓿\rێ/+kso{
ωk;:s!XtMCvC%HyP)>XG&&ko\N?8>h]d@ȿ'ǛnDH>}
5En7Ihm>
m߶"AhjuxPI'oJ͕(|_*LNy`= &I1 b%3"/Dqw(]36L@60[snʄL
řs[Wgh%}z m6,/ꩳ$/yhx D-ؠ7ȁ O63r}Ys%"[)ڣgLxwǀ`sP;٩b@ >IRQAɱb@.," Ay,
|&TkFE
j465w6wm
swo/rګuD<acꔿiWr6!k͜8I3VKԣfS`mJ&>nNa8g OTua݂QVGfA+VN^ez*&`-ɕ~ook J>I`XOp؉VۼM
w6*j]K&V.ǡ:|fN`妵TXiz6bk&p<$M%jt,6O*l.3ݬE$ͮו3ѴRD 9,.}yS
MffSp$/wC
25=mf-xD"RJ> HgVWFqHv8] +[S[-0UP_#Կs FkBб1sv lcل
oa#Lu}Fx)љwƑNhTzǣAb÷gHg9X
=Cf$(7H{y-)+%ll'+FcD=e>]l9IģnTtUA.Gou揚5:qM/QCܭ,m
s)}@bL?ncjh*\nҋ[vo __剴X$K"1
U{V3lZpx3%^~p)q\r5Zio&ֽBuޟJXF5OZ&ѹ"DgKfrf3I,GP]5w9Z*0<%+=jkYv0^Ω%86LK